|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1996-3-27
|
|
pubmed:abstractText |
Therapy-related acute myeloid leukemia (t-AML) is a recognized entity complicating successful therapy for Hodgkin's disease (HD) and other neoplasias after many years. This risk appears to be related to cumulative exposure to alkylating agents and procarbazine, while drugs affecting DNA--topoisomerase II, such as epipodophyllotoxins and anthracyclines, are also associated with t-AML developing after a much shorter latent period.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
777-9
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8589014-Adult,
pubmed-meshheading:8589014-Combined Modality Therapy,
pubmed-meshheading:8589014-Female,
pubmed-meshheading:8589014-Hodgkin Disease,
pubmed-meshheading:8589014-Humans,
pubmed-meshheading:8589014-Karyotyping,
pubmed-meshheading:8589014-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:8589014-Male,
pubmed-meshheading:8589014-Neoplasms, Second Primary,
pubmed-meshheading:8589014-Prognosis,
pubmed-meshheading:8589014-Retrospective Studies,
pubmed-meshheading:8589014-Translocation, Genetic
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin's disease--a report of 4 cases.
|
|
pubmed:affiliation |
Department of Haematology, Hadassah Medical Center, Jerusalem, Israel.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
